- Home
- PTCT vs PTGX Comparison
PTCT vs PTGX Comparison
Compare PTCT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTCT
- PTGX
- Stock Information
- Founded
- PTCT 1998
- PTGX 2006
- Country
- PTCT United States
- PTGX United States
- Employees
- PTCT N/A
- PTGX N/A
- Industry
- PTCT Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- PTCT Health Care
- PTGX Health Care
- Exchange
- PTCT Nasdaq
- PTGX Nasdaq
- Market Cap
- PTCT 4.1B
- PTGX 3.7B
- IPO Year
- PTCT 2013
- PTGX 2016
- Fundamental
- Price
- PTCT $60.65
- PTGX $59.22
- Analyst Decision
- PTCT Buy
- PTGX Strong Buy
- Analyst Count
- PTCT 14
- PTGX 9
- Target Price
- PTCT $67.00
- PTGX $70.44
- AVG Volume (30 Days)
- PTCT 1.2M
- PTGX 925.0K
- Earning Date
- PTCT 11-06-2025
- PTGX 11-06-2025
- Dividend Yield
- PTCT N/A
- PTGX N/A
- EPS Growth
- PTCT N/A
- PTGX N/A
- EPS
- PTCT 7.72
- PTGX 0.80
- Revenue
- PTCT $1,764,929,000.00
- PTGX $209,180,000.00
- Revenue This Year
- PTCT $119.89
- PTGX N/A
- Revenue Next Year
- PTCT N/A
- PTGX $248.17
- P/E Ratio
- PTCT $7.88
- PTGX $73.55
- Revenue Growth
- PTCT 96.00
- PTGX N/A
- 52 Week Low
- PTCT $33.88
- PTGX $33.31
- 52 Week High
- PTCT $62.18
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- PTCT 69.46
- PTGX 55.46
- Support Level
- PTCT $58.87
- PTGX $57.90
- Resistance Level
- PTCT $62.18
- PTGX $60.40
- Average True Range (ATR)
- PTCT 2.13
- PTGX 2.52
- MACD
- PTCT 0.52
- PTGX -0.11
- Stochastic Oscillator
- PTCT 88.43
- PTGX 63.87
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.